Full-Life Technologies Completes Construction of Belgian Radiopharmaceutical Production Facility and Initiates Accelerator Commissioning

Full-Life Technologies (hereinafter referred to as “Full-Life”), a privately held, fully integrated, clinical-stage international radiopharmaceutical therapy company, announced on August 20 that its radiopharmaceutical production facility in Gembloux, Belgium, has completed construction and received authorization to commence accelerator commissioning and enter the initial ramp-up phase.

(Full-Life Technologies Belgium Radiopharmaceutical Production Facility)

This milestone marks a significant step forward in Full-Life's vertically integrated radioisotope production capabilities moving toward formal operational status. With the completion of facility construction, the company has entered the next phase of operational preparation, including accelerator installation, phased commissioning, and validation of critical safety and operational systems.

The accelerator commissioning plan will adopt a phased power ramp-up approach, accompanied by a series of technical and safety assessments to confirm the performance of critical systems prior to routine operations. These efforts represent an important transition of the production facility from the construction phase to the operational qualification phase, ultimately enabling the production of radioisotopes for radiopharmaceutical research, development, and manufacturing.

Philippe van Put, General Manager of Full-Life Technologies Europe, stated: “The completion of the production facility and the initiation of accelerator installation and commissioning represent a significant milestone for Full-Life. Over the past few years, we have built this facility from the ground up, with the goal of establishing a reliable, scalable, and integrated radioisotope supply system for the company's radiopharmaceutical programs. Entering the commissioning phase brings us one step closer to establishing our own production capabilities, thereby supporting our clinical pipeline and ultimately benefiting patients worldwide.”

Full-Life's Belgian production facility is a key component of the company's strategy to build an integrated global radiopharmaceutical platform, aimed at further enhancing the company's self-sufficiency in securing the supply of radioisotopes, including actinium-225 (²²⁵Ac), and providing strong support for its continuously expanding radiopharmaceutical therapy pipeline.